Edwards Lifesciences, the Irvine, California-based medical device company is betting big on the transcatheter mitral valve therapies. On Monday, the structural heart company that dominates the ...
A protracted lull following the flurry of mitral valve acquisitions by the big device companies in 2015 has been broken, this time with news that Edwards Lifesciences has acquired the Israel-based ...
The 30-day outcomes from the TRISCEND study of the transfemoral EVOQUE tricuspid valve replacement system demonstrated technical feasibility and an acceptable safety profile, along with improvements ...
Edwards Lifesciences announced an agreement to acquire Valtech Cardio Ltd., maker of a system for transcatheter repair of mitral and tricuspid valves, for $340 million plus potential milestone ...
Six-month results from the TRI-REPAIR study show potential for the Cardioband percutaneous annuloplasty ring (Edwards Lifesciences) to reduce moderate to severe functional tricuspid regurgitation (TR) ...
IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results